UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$694M |
| 2 |
Apple
AAPL
|
+$615M |
| 3 |
NVIDIA
NVDA
|
+$609M |
| 4 |
Eli Lilly
LLY
|
+$569M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$1.07B |
| 2 |
Tesla
TSLA
|
+$467M |
| 3 |
iShares MSCI ACWI ETF
ACWI
|
+$262M |
| 4 |
Match Group
MTCH
|
+$241M |
| 5 |
Valero Energy
VLO
|
+$212M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.89% |
| 2 | Financials | 8.35% |
| 3 | Healthcare | 6.45% |
| 4 | Consumer Discretionary | 5.39% |
| 5 | Communication Services | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TBI
6051
Trueblue
TBI
$309M
| $151K | ﹤0.01% |
19,128
+7,433
| +64% | +$66.9K |
|
6052
Cardlytics
CDLX
$25.1M
| $151K | ﹤0.01% |
4,715
+726
| +18% | +$40.3K |
|
6053
Village Super Market
VLGEA
$638M
| $151K | ﹤0.01% |
4,741
+1,473
| +45% | +$43.7K |
|
|
OPPJ
6054
WisdomTree Trust WisdomTree Japan Opportunities Fund
OPPJ
$290M
| $150K | ﹤0.01% |
4,429
-59,500
| -93% | -$1.99M |
|
6055
Lyell Immunopharma
LYEL
$337M
| $150K | ﹤0.01% |
5,436
+1,195
| +28% | +$35.1K |
|
6056
Invesco Zacks Mid-Cap ETF
CZA
$193M
| $150K | ﹤0.01% |
1,384
-1,510
| -52% | -$154K |
|
|
PFL
6057
PIMCO Income Strategy Fund
PFL
$385M
| $150K | ﹤0.01% |
17,486
+368
| +2% | +$3.06K |
|
|
ESPR
6058
DELISTED
Esperion Therapeutics
ESPR
| $149K | ﹤0.01% |
90,293
+22,117
| +32% | +$44.7K |
|
6059
Xtrackers MSCI All World ex US Hedged Equity ETF
DBAW
$306M
| $149K | ﹤0.01% |
4,269
| – | – |
|
6060
Innovative Eyewear
LUCY
$6.49M
| $149K | ﹤0.01% |
17,837
+14,767
| +481% | +$88K |
|
|
ETHD
6061
ProShares UltraShort Ether ETF
ETHD
$63.2M
| $149K | ﹤0.01% |
+261
| New | +$156K |
|
6062
Rigel Pharmaceuticals
RIGL
$762M
| $148K | ﹤0.01% |
+9,176
| New | +$108K |
|
6063
Hamilton Beach Brands
HBB
$447M
| $148K | ﹤0.01% |
4,860
+1,032
| +27% | +$25.2K |
|
6064
FT Vest Growth-100 Buffer ETF March
QMAR
$582M
| $148K | ﹤0.01% |
5,164
+4,596
| +809% | +$128K |
|
6065
Gossamer Bio
GOSS
$83.3M
| $148K | ﹤0.01% |
149,835
+149,790
| +332,867% | +$144K |
|
|
EMF
6066
Templeton Emerging Markets Fund
EMF
$332M
| $148K | ﹤0.01% |
10,904
-6,533
| -37% | -$82.8K |
|
|
THRD
6067
DELISTED
Third Harmonic Bio
THRD
| $147K | ﹤0.01% |
10,885
+3,104
| +40% | +$38.5K |
|
6068
AXT Inc
AXTI
$5.07B
| $147K | ﹤0.01% |
60,872
+46
| +0.1% | +$130 |
|
6069
FT Vest US Equity Enhance & Moderate Buffer ETF January
XJAN
$42M
| $147K | ﹤0.01% |
4,419
+4,411
| +55,138% | +$144K |
|
6070
Domo
DOMO
$187M
| $146K | ﹤0.01% |
19,490
-6,433
| -25% | -$49.1K |
|
6071
Nektar Therapeutics
NKTR
$2.57B
| $146K | ﹤0.01% |
7,501
+3,667
| +96% | +$69.9K |
|
6072
Acacia Research
ACTG
$449M
| $146K | ﹤0.01% |
31,372
+13,291
| +74% | +$65.7K |
|
|
FVNNU
6073
Future Vision II Acquisition Corp Units
FVNNU
| $146K | ﹤0.01% |
+14,600
| New | +$146K |
|
|
NYAX
6074
Nayax
NYAX
$2B
| $146K | ﹤0.01% |
5,788
-8,875
| -61% | -$210K |
|
|
LENZ
6075
LENZ Therapeutics
LENZ
$145M
| $146K | ﹤0.01% |
6,145
+2,083
| +51% | +$46.2K |
|
Similar funds
UBS Group's Q3 2024 Portfolio in Review
As of Q3 2024, UBS Group held 10,551 positions worth $459B, up 13% from $405B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
UBS Group deployed $30.4B of net new capital in Q3 2024, opening 1,098 new positions and adding to 4,837 existing holdings. Its largest new stake was Smurfit Westrock: 973,061 shares worth $48.1M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Nike, an estimated $1.07B trimmed.
- UBS Group's largest Q3 2024 buy was Smurfit Westrock: 973,061 shares worth $48.1M.
- UBS Group added most to Meta Platforms (Facebook) in Q3 2024, an estimated $694M increase.
- UBS Group's biggest Q3 2024 reduction was Nike, cutting an estimated $1.07B.
- UBS Group fully exited WestRock Company in Q3 2024, selling an estimated $161M.
- UBS Group's ten largest holdings make up 17% of its $459B portfolio in Q3 2024.
- UBS Group opened 1,098 new positions and closed 1,108 in Q3 2024.
- UBS Group's portfolio value rose 13% quarter-over-quarter to $459B.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.